Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zalsenertant tetraxetan - Fusion Pharmaceuticals

Next Previous
X
Search
Drug Profile

Zalsenertant tetraxetan - Fusion Pharmaceuticals

Alternative Names: 177Lu-DOTA-IPN01087; 3BP-227 Lutetium-177; 3BP227; 111In-IPN01087; 111Indium-labelled IPN01087; 177Lu-3BP-227; 177LU-DOTA-3BP-227; 177Lu-IPN01087; IPN 01087; IPN-01087 - Ipsen; IPN-01087A - Ipsen; Lutetium 177 - IPN 01087; Lutetium Lu 177 DOTA-3BP-227; Lutetium Lu 177 DOTA-IPN01087; Lutetium Lu 177 Zalsenertant tetraxetan; Lutetium-(177lu)-3BP-227; Lutetium-(177lu)-IPN01087; Zalsenertant Tetraxetan Lutetium LU-177

Latest Information Update: 10 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer 3B Pharmaceuticals; Ipsen Biopharmaceuticals
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer in Germany (IV, Infusion)
  • 02 Jun 2021 Ipsen terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in Belgium, france, Netherlands, Switzerland, USA due to transfer of rights under purchase agreement (IV) (EudraCT2017-001263-20) (NCT03525392)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top